# NCT03989414 (NCT03989414)

> A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03989414
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: CC-92480; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib; Elotuzumab; Isatuximab; Carfilzomib
- Enrollment: 424
- Primary outcome: Recommended Dose
- Primary outcome: Recommended regimen as measured by dose-limiting toxicities
- Primary outcome: Number of participants with Adverse Events (AEs)
- Primary outcome: Overall response rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 50
- X threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03989414

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03989414", "email": "<work email>"}; the inbox owner confirms by the emailed link.